Long-term entecavir (ETV) therapy improves liver stiffness measurements (LSMs) in patients with HBeAg-negative chronic hepatitis B (CHB)

被引：0
|
作者：
Papatheodoridis, George V. [1 ]
Goulis, Ioannis [2 ]
Manolakopoulos, Spilios [1 ]
Margariti, Katerina [1 ]
Exarchos, Xenofon [2 ]
Kokkonis, George [2 ]
Papaioannou, Christos [1 ]
Akriviadis, Evangelos A. [2 ]
机构：
[1] Hippokrateion Hosp, Dept Internal Med 2, Athens, Greece
[2] Aristotle Univ Thessaloniki, Dept Med 4, Hippokrat Gen Hosp, GR-54006 Thessaloniki, Greece
来源：
HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
384
引用
收藏
页码：380A / 380A
页数：1
相关论文
共 50 条
  • [31] HBsAg Kinetics Prior to HBsAg Loss after Cessation of Entecavir Therapy in Hbeag-Negative Chronic Hepatitis B Patients
    Jeng, Wen-Juei
    Chang, Ming-Ling
    Liaw, Yun-Fan
    HEPATOLOGY, 2018, 68 : 272A - 272A
  • [32] The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B
    Kose, Sukran
    Tatar, Bengu
    Gul, Selma
    Pala, Emel
    ACTA CLINICA BELGICA, 2016, 71 (04) : 244 - 249
  • [33] Long-term follow-up after initial response to interferon therapy in patients with HBeAg-negative chronic hepatitis B.
    Papatheodoridis, GV
    Manesis, E
    Hadziuannis, SJ
    HEPATOLOGY, 2000, 32 (04) : 378A - 378A
  • [34] Kinetics of Serum Hepatitis B Core Related Antigen (HBcrAg) in Non-Cirrhotic Hbeag-Negative Chronic Hepatitis B (CHBe-) Patients Who Discontinue Effective Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF)
    Papatheodoridi, Margarita
    Berby, Francoise
    Testoni, Barbara
    Hadziyannis, Emilia
    Zachou, Kalliopi
    Lyberopoulou, Aggeliki
    Dalekos, George N.
    Zoulim, Fabien
    Papatheodoridis, George V.
    HEPATOLOGY, 2018, 68 : 265A - 266A
  • [35] Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B
    Fung, J.
    Lai, C. -L.
    Seto, W. -K.
    Wong, D. K. -H.
    Yuen, M. -F.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (10) : 738 - 744
  • [36] Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
    Shouval, Daniel
    Lai, Ching-Lung
    Chang, Ting-Tsung
    Cheinquer, Hugo
    Martin, Paul
    Carosi, Glamplero
    Han, Steven
    Kaymakoglu, Sabahattin
    Tamez, Ricardo
    Yang, Joanna
    Tenney, Daniel
    Brett-Smith, Helena
    JOURNAL OF HEPATOLOGY, 2009, 50 (02) : 289 - 295
  • [37] Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: Results after 5 years of therapy
    Hadziyannis, S
    Tassopoulos, N
    Chang, TT
    Heathcote, J
    Kitis, G
    Rizzetto, M
    Marcellin, P
    Lim, SG
    Goodman, Z
    Arterburn, S
    Ma, J
    Xiong, S
    Borroto-Esoda, K
    Brosgart, C
    Currie, G
    HEPATOLOGY, 2005, 42 (04) : 754A - 754A
  • [38] When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?
    Liaw Y.-F.
    Current Hepatology Reports, 2024, 23 (2) : 221 - 226
  • [39] Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy
    Hadziyannis, Stephanos
    Tassopoulos, Nicolaos
    Chang, Ting-Tsung
    Heathcote, E. Jenny
    Kitis, George
    Rizzetto, Mario
    Marcellin, Patrick
    Lim, Seng Gee
    Goodman, Zachary
    Arterburn, Sarah
    Ma, Jia
    Borroto-Esoda, Katyna
    Mondou, Elsa
    Chuck, Steven
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A23 - A24
  • [40] The correlation between HBeAg levels and entecavir long-term efficacy in chronic hepatitis B patients
    俎燕会
    China Medical Abstracts(Internal Medicine), 2012, 29 (04) : 225 - 225
12345